Press Releases

Life Technologies Acquires UK-Based Matrix MicroScience; Cuts Food Pathogen Testing Workflow and Cost Per Sample by 50 Percent

Untitled Document

CARLSBAD, Calif. – Jan. 24, 2012 – Life Technologies Corporation today announced that it has acquired Matrix MicroScience, a British manufacturer of large-volume, automated sample preparation systems and consumables for the food safety testing industry.

Matrix MicroScience’s technology will be added to Life Technologies’ existing foodborne pathogen detection workflow. The complementary technologies will ultimately help reduce the cost of testing by more than 50 percent and speed up time to results by hours or days in some cases, resulting in lower inventory holding costs for food producers.

Among the key complementary technologies from the British firm is the PATHATRIX AUTO, a benchtop, sample-prep instrument that isolates and concentrates target bacteria in food samples at high volumes with walk-away convenience. The system is designed to work in conjunction with reagent kits that isolate a variety of pathogens, including Salmonella, E. coli O157:H7, Listeria, Cronobacter and Campylobacter. Life Technologies is the leading manufacturer of real-time PCR instruments for the food safety testing market. Its portfolio includes real-time PCR-based detection kits for these same pathogens.

“This acquisition provides all the benefits we were looking for to address our customers’ needs: a solution that dramatically decreases the wait time for results, lowers their price per sample, and makes the technology even more accessible and easy to use for our growing customer base,” said Nir Nimrodi, Vice President and General Manager, Food Safety and Animal Health. 

“Matrix MicroScience’s sample-prep technology is ideally suited for Life Technologies’ broad portfolio of PCR-based pathogen detection kits for the food testing industry,” said Dr. Adrian Parton MBE, CEO of Matrix MicroScience. “It’s a good fit for both organizations and ultimately benefits our customers.”

Not for use in human diagnostic procedures.

About Life Technologies
Life Technologies Corporation is a global biotechnology company dedicated to improving the human condition. Our systems, consumables and services enable researchers to accelerate scientific and medical advancements that make life even better. Life Technologies customers do their work across the biological spectrum, working to advance the fields of discovery and translational research, molecular medicine, stem cell-based therapies, food safety and animal health, and 21st century forensics. The company manufactures both molecular diagnostic and research use only products. Life Technologies' industry-leading brands are found in nearly every life sciences lab in the world and include innovative instrument systems under the Applied Biosystems and Ion Torrent names, as well as, the broadest range of reagents with its Invitrogen, GIBCO, Ambion, Molecular Probes and TaqManÒ products. Life Technologies had sales of $3.6 billion in 2010, has a workforce of approximately 11,000 people, has a presence in approximately 160 countries, and possesses one of the largest intellectual property estates in the life sciences industry, with approximately 4,000 patents and exclusive licenses. For more information on how we are making a difference, please visit our website:

Life Technologies’ Safe Harbor Statement
This press release includes forward-looking statements about our anticipated results that involve risks and uncertainties. Some of the information contained in this press release, including, but not limited to, statements as to industry trends and Life Technologies’ plans, objectives, expectations and strategy for its business, contains forward-looking statements that are subject to risks and uncertainties that could cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Any statements that are not statements of historical fact are forward-looking statements. When used, the words “believe,” “plan,” “intend,” “anticipate,” “target,” “estimate,” “expect” and the like, and/or future tense or conditional constructions (“will,” “may,” “could,” “should,” etc.), or similar expressions, identify certain of these forward-looking statements. Important factors which could cause actual results to differ materially from those in the forward-looking statements are detailed in filings made by Life Technologies with the Securities and Exchange Commission. Life Technologies undertakes no obligation to update or revise any such forward-looking statements to reflect subsequent events or circumstances.

Life Technologies Contact

Mauricio Minotta